Free Trial

10 Best Penny Stocks to Buy Now - 1 of 10

 
 

bluebird bio (NASDAQ:BLUE)

Number of Upgrades from Top-Ranked Analysts
5 (in the last 90 days)
Consensus Rating
Hold
Rating Score
2.3
Ratings Breakdown
4 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$5.74 (535.9% Upside)

About bluebird bio

bluebird bio logobluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
3/27/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$6.00
3/27/2024Wells Fargo & CompanyLower Price TargetEqual Weight ➝ Equal Weight$4.00 ➝ $3.00
3/19/2024WedbushLower Price TargetNeutral ➝ Neutral$1.72 ➝ $1.68
3/5/2024HSBCLower Price TargetReduce ➝ Reduce$2.31 ➝ $1.02
1/9/2024William BlairReiterated RatingMarket Perform
1/8/2024WedbushReiterated RatingNeutral$3.00
12/21/2023Bank of AmericaLower Price TargetBuy ➝ Buy$12.00 ➝ $5.00
12/15/2023Wells Fargo & CompanyLower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.00
12/12/2023Robert W. BairdLower Price TargetOutperform ➝ Outperform$10.00 ➝ $7.00
12/11/2023HSBCDowngradeHold ➝ Reduce
 

This indicator is great for calling bottoms (Ad)

“It was designed to help boost your chances of finding rock solid trade ideas” It’s called the “Master Indicator” And it’s quite possibly one of the most useful indicators you’ll ever use.

If you’d like to join me just follow this link here.